4.6 Article

4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells

期刊

TOXICOLOGY AND APPLIED PHARMACOLOGY
卷 422, 期 -, 页码 -

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.taap.2021.115493

关键词

Breast cancer; Triple-negative breast cancer; Cyclin-dependent kinase 2/4; 4-AAQB

资金

  1. National Science Council of Taiwan [MOST 108-2314-B-038-051-MY3, MOST105-2314-B038-080]
  2. Taipei Medical University-National Taiwan University of Science and Technology Joint Research Program [TMU-NTUST-103-03]
  3. Taipei Medical University [102TMU-SHH-02]

向作者/读者索取更多资源

This study found high expression and alteration of CDK2 and CDK4 significantly correlated with poor prognosis in TNBC patients, and treatment with 4-AAQB can inhibit CDK2 and CDK4, suppressing DNA damage and repair pathways, inducing cell cycle arrest, DNA damage, and apoptosis in TNBC cells. These results indicate that 4-AAQB holds promise as a potential agent for targeting CDK2/4 and DDR in TNBC cells.
Background: Triple-negative breast cancer (TNBC) has a more aggressive phenotype and poorer prognosis than hormone receptor (HR+) and human epidermal growth factor receptor (HER2 -) subtypes. Inhibition of cyclindependent kinase (CDK)4 and CDK6 was successful in patients with advanced metastatic HR+/HER2- breast cancer, but those with TNBC exhibited low or no response to this therapeutic approach. This study investigated the dual therapeutic targeting of CDK2 and CDK4 by using 4-acetyl-antroquinonol B (4-AAQB) against TNBC cells. Methods: We examined the effects of CDK2, CDK4, and CDK6 inhibition through 4-AAQB treatment on TNBC cell lines and established an orthotropic xenograft mouse model to confirm the in vitro results of inhibiting CDK2, CDK4, and CDK6 by 4-AAQB treatment. Results: High expression and alteration of CDK2 and CDK4 but not CDK6 significantly correlated with poor overall survival of patients with breast cancer. CDK2 and CDK4 were positively correlated with damage in DNA replication and repair pathways. Docking results indicated that 4-AAQB was bound to CDK2 and CDK4 with high affinity. Treatment of TNBC cells with 4-AAQB suppressed the expression of CDK2 and CDK4 in vitro. Additionally, 4-AAQB induced cell cycle arrest, DNA damage, and apoptosis in TNBC cells. In vivo study results confirmed that the anticancer activity of 4-AAQB suppressed tumor growth through the inhibition of CDK2 and CDK4. Conclusion: The expression level of CDK2 and CDK4 and DNA damage response (DDR) signaling are prominent in TNBC cell cycle regulation. Thus, 4-AAQB is a potential agent for targeting CDK2/4 and DDR in TNBC cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据